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Hugh W Simpson1,5*, David George2, Robert B Sothern3 and Keith Griffiths4Abstract
We previously described a menstrual heat cycle of the breast in four groups of women (healthy, family history of
breast cancer, benign breast disease, ‘cancer-associated’) who wore a thermometric brassiere (Chronobra). We now
ask if ‘breast minus oral temperature’, indicating ‘breast-associated vascularity’, could be associated with breast
cancer cell vascular access around different aspects of the menstrual cycle rhythm and survival. Thirty-six pre-
menopausal breast cancer patients (average age: 38.97 y) were enrolled consecutively over 15 y and followed for
more than 22 y after surgery in order to compare survival and peri-operative vascularity. Each subject wore the
Chronobra, which provides an internal bioassay of the vascularity of both breasts, including the operated breast,
during 1 h each evening at home for one menstrual cycle, and collected saliva for “free” progesterone to confirm
pre-menopausal status and ovulation. Sixty-five healthy age-matched pre-menopausal women served as controls.
Both oral and breast temperatures revealed menstrual cycle oscillations, rising just before ovulation until menses
onset. Breast-adjusted vascularity also showed menstrual cycle oscillations, with levels differing significantly
between the 3 groups during the luteal phase only. At the end of the follow-up span, 18 post-operative breast
cancer patients had died from “disseminated” breast cancer and 18 were alive and well. Median follow-up time was
22.6 y for survivors, 6.2 y for non-survivors, and 21.0 y for controls (3 died from diseases unrelated to breast cancer).
Based on ‘during luteal-phase breast-adjusted vascularity’, breast cancer survivors (mean ± SD: -1.65 ± 0.23°C)
were significantly hypo-vascular (i.e., -0.23°C cooler) compared with controls (-1.42 ± 0.09°C), while non-survivors
(-1.25 ± 0.12°C) were highly significantly hyper-vascular compared with survivors (+0.41°C warmer) and controls
(+0.23°C warmer). This suggests that in pre-menopausal breast cancer patients, peri-operative mammary vascularity
could offer an outcome test of survival and biologically may be on the “final common pathway” of any tumor to
metastatic risk and recurrence.
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Breast cancer survivalIntroduction
After reviewing an original breast cancer biopsy, a pa-
thologist carrying out a post-mortem examination on a
pre-menopausal woman and finding secondaries in bone,
brain, or viscera, would conclude that the woman had
died of breast cancer disseminated into the blood
stream. The metastasis pattern would raise the question:
what was the access to the vascular system before the* Correspondence: h.simpson257@btinternet.com
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in any medium, provided the original work is pdissemination? Since the initial cancer was in the mam-
mary gland, a superficial modified sweat gland, local sur-
gery might seem like the answer. However, experience in
breast cancer practice is that, no matter how early on or
vigilant the surgery, the cancer all too often catastrophic-
ally disseminates and becomes deadly. Therefore, a more
thorough understanding of the biology of cancer access to
the vascular system is required in order to lead to an im-
provement in the mortality from breast cancer.
We previously described the luteal heat cycle of the
breast in 25 healthy women (Simpson et al. 1993), and
three disease groups: 14 with family history of breasts an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
Figure 1 The Chronobra: a custom built thermometric brassiere
with 16 channel automated electronic thermometry for
measurement of the heat cycle in the breast.
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cer-associated’ group (Simpson et al. 1996). Wearing a
special automatic electronic thermometric brassiere, the
so-called ‘Chronobra’ (Simpson et al. 1981), women mo-
nitored their breast surface temperature during 1 h each
evening at home for one menstrual cycle under stan-
dardized conditions. This instrument measures the vas-
cularity indirectly through the deep heat conducted to
the surface of the breast from the mammary tissue blood
vessels and capillaries. A significant breast temperature
rhythm was found in all four groups, suggesting that there
is an estrogen-driven ebb and flow of pan-mammary vas-
cularity during each menstrual cycle, apparently in a mini-
rehearsal for pregnancy.
There are several possible explanations why a rhythm
in breast vascularity could be associated with breast
cancer cell access stages around different aspects of the
menstrual cycle rhythm. In the luteal phase, the vessels
are larger and it is more likely that the enlarging cancer
will encounter venous capillary walls, and having rea-
ched and penetrated the basement membrane and the
endothelial wall, will effect a thrombotic tumor embolus
in the lumen. During contraction of the vessel wall in
the follicular phase of the cycle, there could be propul-
sion of the tumor onwards into the venous circulation.
The vascularity cycle of the breast has also been related
to the release of histamine in the breast tissue, which
has been associated with chronic cystic mastitis, wherein
cyclic changes in the breast presenting as an increase in
size and turgor are to a considerable extent the result of
a mammary fluid transudate from the permeability ef-
fects of histamine action (Zeppa 1969). This might, in
turn, alter the access of the vessel lumen to the cancer
cells through permeability mechanisms, as in the inflam-
matory process. It is important that the pre-menstrual
timing of the menstrual cycle of breast volume and
water content is the same as the vascularity rhythm
(Simpson et al. 2000). The peak is just before the onset
of the menses, which is about the time of so-called “pre-
menstrual tension”, which may be the risk point for can-
cer access to the circulation.
The current study reports findings from the long-
term follow-up of menstrual cycle Chronobra studies
mentioned above (Simpson et al 1993, 1995, 1996) of 36
pre-menopausal breast cancer cases presenting consecu-
tively in a University Hospital clinic vs. 65 healthy age-
matched controls. Original study measurements were
made daily over one menstrual cycle with parallel mea-
surements of oral temperature, and “free” progesterone
in saliva to confirm the pre-menopausal status of each
woman and the presence of ovulation in each menstrual
cycle studied. All patients were followed for more than
two decades post-operatively, by which time half had
died of disseminated breast cancer according to thedeath certificate. Since the breast minus oral tempera-
ture represents the breast-specific temperature after ad-
justing for arterial blood temperature, we performed this
calculation for each daily measurement to arrive at indi-
vidualized breast vascularity values. Comparisons were
then made between menstrual cycle vascularity in sur-
viving vs. non-surviving patients vs. controls and bet-
ween patients to see if vascularity influenced survival.Methods
Subject recruitment
All recruitment procedures have been previously re-
ported (Simpson et al 1993, 1995, 1996). Briefly, follow-
up patients in the pre-menopausal age group were
recruited when presenting at the University Hospital
Breast Clinic, resulting in 36 women in the breast cancer
group. 65 healthy controls were volunteers recruited
from church groups and by word of mouth about the
project in the University environment. All subjects were
white Caucasian, pre-menopausal, and usually parous. In
the selection process of subjects, an understanding of
the breast cancer problem and what might be achieved
was important to capture their enthusiasm and their re-
sponsibility for the accuracy of tabulated data and also
to have the stamina to complete the day-by-day mea-
surements for a complete menstrual cycle on a voluntary
basis without payment.Data collection
In order to study the daily vascularity of the breast
for one menstrual cycle in each woman, a specific tech-
nique was developed and has previously been reported
(Simpson et al. 1993; Simpson et al. 1996). Briefly,
the Chronobra, a custom-built thermometric brassiere
(Figure 1), was built with a marsupial pouch between
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and time clock, a sampling speed control device (e.g.,
every minute), and a semi-conductor memory storage
chip. Different bra sizes were available, but the instru-
mentation package embedded in the bra was the same.
Figure 1 shows 14 breast thermometry sensors on the in-
side of the bra, while there were two additional channels
on the front to check the use of standardized provided
clothing and ambient temperature. Occasional mainten-
ance was required for mending wire breakage after normal
usage and recalibration, resulting in 15% of the data mis-
sing for technical and/or compliance reasons.
Subjects were asked to collect temperature measure-
ments in their home for 90-min each evening through
one menstrual cycle by wearing the Chronobra with
standardized provided over-clothing. Each study began
soon after their last menstrual period, with the cycle
“day” recorded at the top of a daily log sheet, using +1
as the first day of the menses and so on. After a preli-
minary 30-min span, they were required to remain
seated and read or watch television for an hour while
the instrument recorded the prevailing surface breast
temperature. At the end of each 90-min span, they were
asked to switch off the Chronobra and to record the
time and room temperature from a provided desktop in-
strument on a nearby table. They then measured and
recorded their oral temperature (using two thermome-
ters: digital and mercury), regarded as representing the
carotoid blood temperature. The log sheet also included
a section to note any interfering events during the re-
cording hour of study.
Twice weekly a nurse would visit the home, exchange
the instrument for a fresh one and bring the existing in-
strument back to the laboratory for data downloading,
where a program picked out the peak plateau tempera-
ture recorded by the bra each day, representing the point
at which there is equilibration between the sensor and
the deep breast temperature. The same principle is in-
volved in the so-called deep body thermometry tech-
nique used in patients who have been exposed to
hypothermic situations e.g., avalanche accidents, which
enables medical attendants to obtain non-invasively the
deep body temperature (Fox et al. 1973). Each subject
also collected a daily saliva sample for a “free” pro-
gesterone radioimmunoassay (Reid et al. 1985). The
Kaiser-Minnesota-Kyushu Breast Cancer Epidemiolo-
gical Questionnaire (Kaiser 1981) was filled out for details
involving the reproductive lifestyle of each subject, preg-
nancy histories, oral contraceptive practice, menstrual per-
iodicity, pregnancy dates and any drugs being used. Also,
a Nottingham Prognostic Index score based on tumor
characteristics (cancer size, grade & lymph nodes) was cal-
culated for each patient (Elston & Ellis 1991; Haybittle
et al. 1982).Follow-up of subjects
The 36 patients and the 65 healthy controls were fol-
lowed up through hospital records and the Government
Academic Registrar-of-Deaths Bureau. At 22.8 y post-
operative follow-up, 18 patients had died, and had “dis-
seminated breast cancer” on the death certificate and the
other 18, all aged over 60 y, were alive and well. In the
same span, three of the controls died of causes unrelated
to breast cancer (cardiac disease, hypercholesterolemia
and mesothelioma).Statistics
Data were averaged if available from both breasts on any
day. Since the temperature recorded at the breast surface
by the Chronobra represents the deep temperature of
the breast that is related to the vascularity of the mam-
mary tissue, the breast minus oral temperature repre-
sents the ‘breast-specific’ temperature. We therefore
calculated breast minus oral temperature for each daily
measurement to arrive at individualized breast vascular-
ity values. This “normalizing” procedure also minimized
any differences between women due to overall body
temperature levels that are affected by a set point in
each woman originating in the hypothalamus.
The menstrual cycles of the individuals ranged from
19d to 39d and in order to achieve synchronization of
the cycles for averaged data, each individual’s calendar
date of menses onset at the end of the study was
counted as day +1, and days before that referred to as
day -1, -2, -3, back to day -28. This backwards syn-
chronization method takes advantage of the fact that the
length of the luteal phase of the menstrual cycle across
different women is comparatively constant (i.e., 12-14d),
while there is greater variation in the length of the fol-
licular phase. The daily progesterone values served to
confirm the pre-menopausal status and an ovulatory
cycle in each subject during the study, thus forming a
check on the synchronization across women with ovu-
lation occurring just before the rise of progesterone
(around day -12).
Daily means were calculated for each variable (oral
temperature, breast temperature, vascularity, progeste-
rone) and group (controls, survivors, non-survivors) on
each day of the menstrual cycle from days -28 to +2.
Menstrual cycle rhythm characteristics were determined
by the least-squares fit of a 28d cosine (Mojón et al.
1992) to individual and overall grouped data for each
variable and study groups were compared. In addition,
vascularity data during the luteal phase only (days -11
to -1 from menses onset) were analyzed by two-tailed,
unpaired t-tests to compare vascularity between study
groups during this elevated heat-related portion of the
menstrual cycle.
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Healthy controls: the physiological menstrual cycle of
breast vascularity
Daily mean values for right and left breast temperatures
and salivary progesterone are shown in Figure 2 for the
healthy control group. The menstrual cycle vascularity
rhythm is characterized by a steady rise in similar tem-
perature of both breasts beginning close to the time of
ovulation until just prior to the onset of the next men-
ses. For this reason, we averaged the temperatures from
the two breasts when available to arrive at one value/
woman/day to use in further calculations. The extent of
the rise of the breast temperature in the luteal phase is
about 1°C (2.2°F), due partially to an increasing vascu-



































































Figure 2 The menstrual cycle of salivary progesterone and deep brea
pre-menopausal controls. Chronobra data shown for days -20 to -1 fromexploited in the so-called “safe period” of contraception.
However, since changes in basal body temperature
amount to only about 1/3°C, much of the rise seen after
ovulation in Figure 2 is assumed to be associated with
increased breast vascularity. Progesterone also shows the
anticipated rise to a peak in the middle of the luteal
phase.
Breast cancer survivors vs. non-survivors
Individual ages, post-op follow-up (survival) years, and
tumor pathology results for survivors and non-survivors
are listed in Table 1, while overall group means and
comparisons are summarized in Table 2. The median
post-op survival was 22.7 y for survivors and 6.62 y
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ht Breast Temp (n = 65)
gesterone (n = 64)
st temperature (left versus right breast) in 65 healthy
menses onset to emphasize higher values during the luteal phase.
Table 1 Breast cancer characteristics and outcomes 22.4 y post-operation for 18 survivors and 18 non-survivors
SURVIVORS (invasive, n = 15: in situ, n = 3) NON-SURVIVORS (invasive n = 18)
































54.15 15.39 15 2 1 4.30 41.87 0.76 120 3 2 7.40
40.84 19.12 50 1 0 3.00 46.46 1.16 21 3 4 6.42
36.48 19.39 80 3 0 5.60 39.61 1.90 40 3 2 5.80
41.68 19.93 20 3 0 4.40 37.83 2.28 15 3 0 4.30
32.70 20.32 * 3 0 In situ 56.57 2.50 20 3 5 6.40
40.08 20.50 8 2 0 3.16 26.90 2.69 20 3 1 5.40
37.50 20.67 28 3 0 4.56 43.78 4.21 18 2 0 3.36
34.23 21.04 35 2 0 3.70 28.07 5.43 19 2 0 3.38
42.97 21.96 * - 0 In situ 38.45 5.60 30 3 1 5.60
42.26 23.35 * - 0 In situ 37.45 6.79 25 3 0 4.50
41.15 23.50 10 (?) 3 0 4.20 43.69 8.01 30 1 1 3.60
36.76 24.08 35 2 0 3.70 39.22 8.07 30 3 1 5.60
34.80 24.38 20 3 0 4.40 40.73 8.46 15 2 0 3.30
32.47 24.83 8 3 0 4.16 44.02 9.32 15 2 0 3.30
34.84 25.04 30 3 0 4.60 42.43 13.11 45 3 1 5.90
35.98 25.41 40 3 0 4.80 38.46 15.73 8 2 0 3.16
38.03 26.19 57 2 0 4.15 31.75 21.16 10 3 0 4.20
34.08 28.14 10 3 0 4.20 34.59 22.82 15 3 0 4.30
*Score not possible where cancer was “in situ” (i.e., non-invasive).
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(p = 0.01), but there were no significant differences bet-
ween the two groups for age at surgery, tumor size, grade
or Nottingham Prognostic Index.
Figure 3 illustrates the full menstrual cycle time plots
of the peri-operative mammary vascularity of the 18 sur-
vivors vs. the 18 non-survivors. For this figure, 3d mo-
ving averages were calculated for clarity, since some
single days contained unequal numbers of women due
to missed during data collection (see Methods). The 3-day
moving mean&SE’s are overprinted with a best-fitting 28d
cosine for each group that provides rhythm characteristicsTable 2 Summary of study parameters and tumor characteris
Parameter Units 18 Sur
[N] Mea
Age at surgery Years [18] 38
Size mm [15] 29.7
Grade 1-3 [16] 2.56
Nodes N [18] 0.06
Nottingham Prognostic Index Score [15] 4.20
Survival Years [18] 22
(Medianof overall adjusted mean (MESOR =middle of cosine),
amplitude (half the distance from trough to peak of co-
sine) and acrophase (peak of cosine). Figure 3 shows that
while breast vascularity levels prevailing peri-operatively
showed significant menstrual cycle oscillation in both pa-
tient groups, with highest values during the luteal phase,
overall vascularity levels were lower (mean = -1.81°C) in
those subsequently surviving more than two decades
after surgery and higher (mean = -1.49°C) in those dying
with “disseminated breast cancer” during that time span
(p < 0.0001). Note: since the values represent the °C below
oral (arterial) temperature, high negative values are cooler.tics for 36 pre-menopausal breast cancer outcomes
vivors 18 Non-survivors p-value from
n ± SD [N] Mean ± SD t-test
.4 ± 5.2 [18] 39.6 ± 6.8 0.5695
± 20.7 [18] 27.6 ± 25.1 0.7899
± 0.63 [18] 2.61 ± 0.61 0.8203
± 0.24 [18] 1.00 ± 1.46 0.0103
± 0.64 [18] 4.77 ± 1.32 0.1308
.4 ± 3.1 [18] 7.8 ± 6.6 <0.0001






























































non Survivors (n = 18)
Figure 3 The menstrual cycle of breast vascularity (oral temperature minus breast temperature, °C) for 36 pre-menopausal breast
cancer patients: 18 Survivors vs. 18 Non-Survivors after 22.8 y. Best-fitting cosine describes a significant 28d pattern for each group, with
highest values during the luteal phase and overall vascularity significantly higher for non-survivors (-1.49 vs. -1.81°C, p <0.0001). Note: 3d moving
averages shown for clarity.
Table 3 Comparison of luteal phase vascularity values
(breast temperature minus oral temperature, °C) on
menstrual cycle days -11 to -1 from menses (M) onset
Day from Non-survivors Controls Survivors
M onset (n = 18) (n = 65) (n = 18)
−11 −1.20 −1.53 −1.66
−10 −1.31 −1.47 −1.56
−9 −1.36 −1.58 −1.56
−8 −1.01 −1.49 −1.63
−7 −1.29 −1.42 −1.38
−6 −1.21 −1.44 −1.71
−5 −1.29 −1.39 −1.83
−4 −1.28 −1.32 −1.54
−3 −1.42 −1.34 −1.41
−2 −1.11 −1.38 −1.64
−1 −1.21 −1.29 −2.22
Mean (°C) ± SD −1.25° ±0.12 −1.42° ±0.09 −1.65° ±0.23
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days -11 to -1 from menses onset), are listed in Table 3.
Based on ‘during luteal-phase breast-adjusted vascula-
rity’, breast cancer survivors (mean ± SD: -1.65 ± 0.23°C
[-3.63°F]) were significantly hypo-vascular (i.e., -0.23°C
[0.41°F] cooler) compared with controls (-1.42 ± 0.09°C
[-3.12°F]) (p < 0.001), while non-survivors (-1.25 ± 0.12°C)
(-2.75°F) were highly significantly hyper-vascular com-
pared with survivors (+0.41°C [0.73°F] warmer) (p < 0.001)
and controls (+0.18°C [0.39°F] warmer) (p = 0.006).
The corresponding progesterone values have similar
menstrual cycle characteristics with regard to overall
level, amplitude and acrophase for survivors and non-
survivors (Figure 4) and confirm the ovulatory status of
the cycles studied. There were no significant differences
between the two patient groups for any of the three
rhythm characteristics.
Data from a patient who developed clinical breast cancer
after study
In the methods section, three pre-menopausal breast
cancer patients are included whose Chronobra data
happened to be collected before the onset of clinically-
evident cancer. One of these patients was being inves-
tigated for sub-fertility and in vitro fertilization and
agreed to complete a menstrual cycle of Chronobra mea-
surements when she was age 36.9 y. The cancer was
Figure 4 The menstrual cycle of salivary progesterone for 18 breast cancer survivors vs. 18 non-survivors. Best-fitting cosine describes a
significant 28d pattern for each group, with highest values during the luteal phase and no significant differences in overall progesterone levels
(163 vs. 157 pM/L, p = 0.4869). Note: 3d moving averages shown for clarity.
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ease 2.5 y later. Daily measurements of plasma estradiol,
serum progesterone, salivary progesterone and breast
vascularity were obtained (Figure 5). While her proges-
terone pattern was normal, with a peak in the mid-luteal
phase, the breast vascularity started to rise before ovula-
tion (day 13 of the cycle, about the time of the estradiol
surge), which is in contrast to the breast temperature
vascularity of the healthy controls (Figure 2), where the
progressive hyper-vascularity occurs in the two weeks
after ovulation.
Previously we reported (Simpson et al. 1996) that a
phase-advance of vascularity by 2.2d relative to ovulation
is a characteristic of “cancer-associated” breasts (defined
as either breast in a patient with cancer or history of
previous cancer diagnosis). In the present series of data
there was a similar trend, indicating that the same signal
relates to the outcome of breast cancer patients. Analysis
of peak times (acrophases) found significant differences
for phase relationships in vascularity between the three
groups in our study, with the peak for cancer survivors
(day 21.5 after menses onset) and non-survivors (day 20.1)
preceding that in controls (day 27.4) by 5.9d and 7.3d,
respectively. These results could suggest that the cancer
risk and outcome risk are related to hyper-responsiveness
of mammary vascularity during the estrogen-mediated
part of the cycle.Discussion
We studied 36 pre-menopausal patients with breast
cancer, of which 33 had invasive disease. The study
employed the Chronobra electronic thermometry instru-
ment that was worn by subjects each evening at home
for one menstrual cycle. The design was to enroll cancer
patients as they presented, usually post-operatively, but
sometimes pre-operatively, and therefore unstratified.
Thirty-six cases were enrolled consecutively with an
average age of 38.97 y. The study was not blinded, but
since death from disseminated breast cancer was the
endpoint, the input data could not be biased in advance.
The time span over which cases were enrolled was 15 y
and the end of the 22.8 y follow-up span was in 2012,
when 18 of the 36 post-operative breast cancer patients
had died with “disseminated breast” cancer on their death
certificate (SM8) and 18 were alive and well.
As soon as the patients were enrolled at the breast
clinic where there were both new cancer cases and
follow-up cases, there was a tendency to enroll longer
follow-up cases that had become potential survivors. In
other words, those eventually classified as survivors
might have incorporated a “confounding” vascularity sig-
nal because of the different delay in the Chronobra study
after operation, e.g., due to the menopause onset. How-
ever, the average elapsed time of the eventual survivors






























































































































Figure 5 Individual example of daily breast vascularity, salivary progesterone and plasma oestradiol over one menstrual cycle for a
patient, age 36.9 y at Chronobra study, that developed breast cancer 20 y later at age 56.5 y and died 2.5 y later from the disease at
age 59.1 y.
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since in the decade preceding the menopause, breast
temperature has been reported to remain fairly steady
(Simpson 1996). On this basis, when three subjects pre-
viously enrolled as pre-menopausal “controls” developed
clinical breast cancer afterwards (7.6, 16.5, 19.7 y later),they were included with the original 33 subjects studied
after surgery to increase the breast cancer patient group
size to 36. In addition, previously published studies of
breast vascularity in healthy controls indicated that,
whereas there is a tendency for a rise during the re-
productive life years, nevertheless there is a plateau
Simpson et al. SpringerPlus 2013, 2:241 Page 9 of 10
http://www.springerplus.com/content/2/1/241(Simpson 1996) of vascularity from the late 30s to the late
40s, followed by a substantial fall at the menopause.
Taking account of this plateau and the progesterone-
checked pre-menopausal status of all 36 subjects, it was
considered reasonable to include all 36 patients in the
study whether or not the Chronobra was used before or
after the operation.
As the data were collected from controls, it was no-
ticeable that the right and left breast readings were very
similar on any one day. This was also true in patients
where local removal of the cancer left both breasts to
record from. On the other hand, there was a substan-
tial difference between the breasts of different subjects
(range = 2.36°C) and this underscores the point that
healthy controls exhibit a wide variation of background
prevailing vascularity in their breasts during their men-
strual cycle in the pre-menopausal years, and most likely
at any breast cancer operation. This emphasizes the im-
portance of normalizing “breast-associated vascularity”
for each woman by subtracting oral temperature from
breast temperature, which presumably standardizes the
outcome values from different patient’s body set points.
A difference between the survivors and non-survivors
was found in their estimated peri-operative breast vascu-
larity during the menstrual cycle, especially during the
luteal phase, probably prevailing before and after the
breast cancer operation. Survivors were hypo-vascular
and the non-survivors hyper-vascular when compared
with each other and with the controls. This finding sug-
gests that survival might depend on the prevailing breast
tissue vascularity existing pre- and post-operation and
be the “inherited” survival factor described by Hartman
(Hartman et al. 2007). This implies a connection be-
tween vascularity and cancer penetration of the blood
vessel wall, since in hyper-vascularity there is a greater
area vessel wall for cancer to encounter. After vascular
invasion, two factors could further contribute to tumor
dissemination: 1) greater exiting venous blood flow fromFigure 6 Histological picture of breast cancer involving veins. “B” show
that each cancer cell can just be perceived as an indigo dot about 10 micr
by a thrombus, and “D” and possibly “A”, the tumor thrombus has a long tthe breast in hyper-vascularity, and 2) rhythmic men-
strual cycle effect on the mammary vein walls. This sce-
nario is to some extent captured in the histological
picture of breast cancer involving two veins (Figure 6),
wherein “B” shows the cancer itself with microscopic
magnification adjusted so that each cancer cell can just
be perceived as an indigo dot about 10 microns in size,
while “C” and “D” show veins involved with cancer and
enlarged by a thrombus. In “D” and possibly “A”, the
tumor thrombus has a long tail and during the men-
strual cycle, with the veins alternatively contracting and
expanding, it is reasonable to suggest that pieces of the
tail will break off into the general circulation.
Our results show that contra-lateral breasts after can-
cer mastectomy were hyper-vascular in the 50% of pa-
tients with ultimately a poor prognosis (i.e., death from
disseminated breast cancer). Published archival histo-
pathological studies indicate that such cancer-associated
breasts have a greatly increased risk of oestrogen-related
multi-focal sub-clinical epithelial hyperplasia. This hy-
perplasia may be involved in the observed hyper-vascu-
larity. Our data indicate that pre-menopausal women
with physiologically hyper-vascular mammary levels dur-
ing the luteal phase of the menstrual cycle and are ope-
rated on for breast cancer, are more likely to die of
disseminated cancer in the post-operative years than
others of the same age with hypo-vascular breasts. We
have previously shown that cancer-associated breasts in
the pre-menopausal years are more likely to contain hy-
perplastic, as well as neoplastic, epithelial elements
(Simpson et al. 1982), and it may be that these elements
contribute to the hyper-vascularity, since presumably
both are related to excess oestrogen responsiveness.
In conclusion, our results suggest that pre-menopausal
healthy women and both surviving and non-surviving
breast cancer patients all exhibit a menstrual cycle of
vascularity in their breast tissue that is systematically
lower peri-operatively in patients that do not go on tos the cancer itself with the microscopic magnification adjusted so
ons in size, “C” and “D” show veins involved with cancer and enlarged
ail.
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perience a disease recurrence and ultimately succumb to
the disease over the two decades following surgery. This
implies a connection between the breast menstrual cycle
vascularity rhythm and the vascular invasion of a cancer.
Consequently, in pre-menopausal breast cancer patients,
peri-operative breast vascularity measured by a device
such as the Chronobra could offer a prognostic out-
come test of survival and biologically implicating hyper-
vascularity as being on the “final common pathway” of
any tumor to metastatic risk and recurrence (Simpson
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